Erratum: Novo awaits green light for diabetes drug

  • Mike May
  • Published 2009 in Nature Biotechnology

Abstract

In the version of this article initially published, GLP-1 was incorrectly described as “glucose-lowering peptide-1”; the correct definition is “glucagonlike peptide-1.” The article also stated incorrectly that Amylin and Lilly “filed a new drug application for this drug in July...” referring to Exenatide Once Weekly. This should be corrected to “their new drug application was accepted for review by the FDA in July....” The error has been corrected in the HTML and PDF versions of the article. errata

DOI: 10.1038/nbt1009-957c

Cite this paper

@article{May2009ErratumNA, title={Erratum: Novo awaits green light for diabetes drug}, author={Mike May}, journal={Nature Biotechnology}, year={2009}, volume={27}, pages={957-957} }